Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
We can see a decrease in the price for Akebia Therapeutics Inc.. Compared to yesterday it has lost -€0.018 (-2.340%).
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Akebia Therapeutics Inc..
With a target price of 4 € there is potential for a 431.77% increase which would mean more than doubling the current price of 0.75 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | -2.340% | -33.078% | -37.343% | -72.746% | -43.613% | -34.477% | -66.117% |
| Heron Therapeutics Inc. | -2.820% | -30.549% | -20.492% | -75.000% | -73.878% | -80.470% | -96.894% |
| Evolus Inc | -0.400% | 26.997% | 21.713% | 31.358% | 27.743% | -21.775% | -21.775% |
| Rhythm Pharmaceuticals | -0.990% | 5.820% | 6.383% | 23.457% | 6.952% | 309.836% | 754.701% |
Comments
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo revenue rose sharply to $21.3 million in Q2 2026, up 34% sequentially and 60% year over year
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo uptake is improving, with Akebia saying the number of prescribing physicians rose 28% to about